97 related articles for article (PubMed ID: 32344898)
1. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
Anwar A; Lepore C; Czerniecki BJ; Koski GK; Showalter LE
Cell Immunol; 2024; 397-398():104805. PubMed ID: 38244265
[TBL] [Abstract][Full Text] [Related]
2. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
J Pediatr Surg; 2024 Mar; ():. PubMed ID: 38570263
[TBL] [Abstract][Full Text] [Related]
3. Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer.
Murakami K; Furuya H; Hokutan K; Goodison S; Pagano I; Chen R; Shen CH; Chan MWY; Ng CF; Kobayashi T; Ogawa O; Miyake M; Thornquist M; Shimizu Y; Hayashi K; Wang Z; Yu H; Rosser CJ
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902377
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
Sci Rep; 2020 Sep; 10(1):14380. PubMed ID: 32873828
[TBL] [Abstract][Full Text] [Related]
5. Single-cell RNA sequencing reveals SERPINE1-expressing CAFs remodelling tumour microenvironment in recurrent osteosarcoma.
Huang X; Wang L; Guo H; Zhang W
Clin Transl Med; 2024 Jan; 14(1):e1527. PubMed ID: 38193644
[No Abstract] [Full Text] [Related]
6. Translating Senotherapeutic Interventions into the Clinic with Emerging Proteomic Technologies.
Dey AK; Banarjee R; Boroumand M; Rutherford DV; Strassheim Q; Nyunt T; Olinger B; Basisty N
Biology (Basel); 2023 Oct; 12(10):. PubMed ID: 37887011
[TBL] [Abstract][Full Text] [Related]
7. Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway.
Chen S; Morine Y; Tokuda K; Yamada S; Saito Y; Nishi M; Ikemoto T; Shimada M
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195849
[TBL] [Abstract][Full Text] [Related]
8. ERRα promotes pancreatic cancer progression by enhancing the transcription of PAI1 and activating the MEK/ERK pathway.
Liu SL; Wu XS; Li FN; Yao WY; Wu ZY; Dong P; Wang XF; Gong W
Am J Cancer Res; 2020; 10(11):3622-3643. PubMed ID: 33294258
[TBL] [Abstract][Full Text] [Related]
9. [Established data and practical recommendations concerning pre- and postoperative chemotherapy of rectal cancer].
Rougier P; Mitry E; Clavéro-Fabri MC; Penna C; Nordlinger B
Ann Chir; 1999; 53(10):1011-8. PubMed ID: 10670150
[TBL] [Abstract][Full Text] [Related]
10. PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208.
Muñoz-Galván S; Rivero M; Peinado-Serrano J; Martinez-Pérez J; Fernández-Fernández MC; Ortiz MJ; García-Heredia JM; Carnero A
Cells; 2020 Apr; 9(5):. PubMed ID: 32344898
[TBL] [Abstract][Full Text] [Related]
11. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
12. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
Lee M; Lee KH; Min A; Kim J; Kim S; Jang H; Lim JM; Kim SH; Ha DH; Jeong WJ; Suh KJ; Yang YW; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Res Treat; 2019 Apr; 51(2):451-463. PubMed ID: 29879757
[TBL] [Abstract][Full Text] [Related]
13. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
14. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
